| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
Purity: ≥98%
| Targets |
D3 Receptor ( Ki = 0.71 nM ); D2 Receptor ( Ki = 4-15 nM ); D5 Receptor ( Ki = 4-15 nM ); D4 Receptor ( Ki = 4-15 nM ); D1 Receptor ( Ki = 83 nM ); α1A ( Ki = 176 nM ); α1B ( IC50 = 273 nM ); α2A ( IC50 = 338 nM ); α2B ( IC50 = 27 nM ); 5-HT1A Receptor ( Ki = 30 nM ); 5-HT7 Receptor ( Ki = 86 nM )
Rotigotine hydrochloride targets dopamine receptors. It has Ki values of 13 nM for D2 and 0.71 nM for D3 receptors. It also has significant affinity for 5-HT1A and adrenergic α2B receptors. It is a partial agonist at the 5-HT1A receptor and an antagonist at the α2B-adrenergic receptor. By stimulating dopamine receptors, it increases dopamine levels in the brain. |
|---|---|
| ln Vitro |
Rotigotine (N-0923) exhibits a selectivity of ten times for D3 (pKi 9.2) receptors in comparison to D2, D4, and D5 (pKi 8.5-8.0) receptors, and a hundred times for D1 receptors (pKi 7.2). Rotigotine (N-0923) exhibits full agonist behavior at all dopamine receptors in functional studies; however, it is noteworthy that the potency of D1 receptor stimulation is comparable to that of D2 and D3 receptors (pEC50: 9.0, 9.4-8.6, 9.7)[1]. In primary mesencephalic cell culture, rotigotine (N-0923) (10 µM) reduces the number of THir neurons by forty percent. Rotigotine (0.01 µM) significantly inhibits rotenone-induced ROS production, significantly protects dopaminergic neurons against MPP+ toxicity, and mildly protects dopaminergic neurons against rotenone-induced cell death[4].
In vitro, rotigotine hydrochloride is a potent agonist of dopamine receptors. Its Ki values are 83 nM for D1, 13 nM for D2, and 0.71 nM for D3. It also has affinity for D4 and D5 receptors (4-15 nM). It is a partial agonist at the 5-HT1A receptor and an antagonist at the α2B-adrenergic receptor. Its activity is confirmed in receptor binding and functional assays. |
| ln Vivo |
Rotigotine (N-0923) (0.035, 0.1, and 0.35 mg/kg) dose-dependently produces contralateral turning behavior in primed rats. Compared to primed rats, drug-naive rats exhibit less turning behavior when Rotigotine is administered alone or in conjunction with SCH 39166[3]. |
| Enzyme Assay |
In 96-well polypropylene tubes, binding assays are carried out with a final volume of 2 mL for D1 and D4 membranes and 1 mL for D2, D3, and D5 membranes. These tubes contain the following materials: 50 μL radioligand, 10 μL drug/buffer/non-specific binding, buffer (final concentration 50 mM Tris-HCl pH 7.4, MgCl2 2 mM), and membranes (5 μg protein for D2 and D3 and 25 μg protein for D1 and D5). Rapid vacuum filtration through A/C glass fiber filters presoaked in 0.1% polyethylenimine is used to determine bound radioligand after 120 minutes of incubation at 25°C. Liquid scintillation counting is used to determine the retained radioactivity after the filters are four times cleaned with 2 mL of ice-cold ishing buffer (Tris-HCl 50 mM, pH 7.4 at 4°C).
Cell-free assays for rotigotine hydrochloride measure its binding affinity to dopamine receptors. Radioligand binding assays are used to determine its Ki values for D1, D2, D3, D4, and D5 receptors. Its affinity for 5-HT1A and α2B-adrenergic receptors is also measured. Its molecular weight (351.934) and formula (C19H26ClNOS) are confirmed by mass spectrometry. |
| Cell Assay |
Cellular assays for rotigotine hydrochloride are used to study its functional activity. Its ability to activate dopamine receptors is measured by assessing downstream signaling pathways, such as cAMP inhibition. Its partial agonist activity at the 5-HT1A receptor and antagonist activity at the α2B-adrenergic receptor are also confirmed in functional cellular assays.
|
| Animal Protocol |
Primed rats: Two weeks following the 6-OHDA lesions, rats receive a 0.5 mg/kg s.c. apomorphine priming. Rats that perform fewer than 150 contralateral rotations in the course of the one-hour testing session are not included in the research. Three days following priming, rats are split up into several experimental groups and given varying dosages of either rotigotine or pramipexole, which are dopamine receptor agonists alone or in conjunction with D1 (SCH 39166) or D2 (eticlopride) receptor antagonists, as previously reported: saline+Rotigotine (0.035 mg/kg s.c., n=9; 0.1 mg/kg s.c., n=9; 0.35 mg/kg s.c., n=8); SCH 39166 (0.1 mg/kg s.c.)+Rotigotine (0.035 mg/kg s.c., n=5; 0.1 mg/kg s.c., n=7; 0.35 mg/kg s.c., n=5); eticlopride (0.1 mg/kg s.c.) + Rotigotine (0.1 mg/kg s.c., n=5; 0.35 mg/kg s.c., n=5); Saline+pramipexole (0.035 mg/kg s.c., n=5; 0.1 mg/kg s.c., n=12; 0.35 mg/kg s.c., n=7); SCH 39166 (0.1 mg/kg s.c.)+pramipexole (0.035 mg/kg s.c., n=5; 0.1 mg/kg s.c., n=6; 0.35 mg/kg s.c., n=6); eticlopride (0.1 mg/kg s.c.)+pramipexole (0.1 mg/kg s.c., n=7; 0.35 mg/kg s.c., n=5). |
| ADME/Pharmacokinetics |
Rotigotine hydrochloride has a molecular weight of 351.934 and a molecular formula of C19H26ClNOS. It is a potent agonist of dopamine receptors. It is administered as a transdermal patch, providing continuous drug delivery. It is a white to off-white solid powder. It is soluble in water and organic solvents. It should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
The toxicological profile of rotigotine hydrochloride is consistent with that of dopamine agonists. Common side effects include nausea, vomiting, dizziness, and somnolence. It can also cause impulse control disorders and skin reactions at the application site. Its safety has been established in clinical trials for Parkinson's disease.
|
| References |
|
| Additional Infomation |
Rotigotine hydrochloride is a dopamine D2 and D3 receptor agonist used for the treatment of Parkinson's disease. It is also known as N-0923 Hydrochloride. It is administered as a transdermal patch, providing continuous drug delivery. It is an approved drug in many countries for the treatment of Parkinson's disease and restless legs syndrome.
|
| Molecular Formula |
C19H26CLNOS
|
|---|---|
| Molecular Weight |
351.93
|
| Exact Mass |
351.142
|
| Elemental Analysis |
C, 64.84; H, 7.45; Cl, 10.07; N, 3.98; O, 4.55; S, 9.11
|
| CAS # |
125572-93-2
|
| Related CAS # |
Rotigotine; 99755-59-6; Rotigotine-d7 hydrochloride
|
| PubChem CID |
180335
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
470.1ºC at 760 mmHg
|
| Melting Point |
186.5-187.5ºC
|
| Flash Point |
238.1ºC
|
| Vapour Pressure |
1.84E-09mmHg at 25°C
|
| LogP |
5.067
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
23
|
| Complexity |
337
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
OC1=C2CC[C@@H](CC2=CC=C1)N(CCC3=CC=CS3)CCC.[H]Cl
|
| InChi Key |
CEXBONHIOKGWNU-NTISSMGPSA-N
|
| InChi Code |
InChI=1S/C19H25NOS.ClH/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21;/h3-7,13,16,21H,2,8-12,14H2,1H3;1H/t16-;/m0./s1
|
| Chemical Name |
(6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol;hydrochloride
|
| Synonyms |
Rotigotine Hydrochloride; N 0923; N-0923; N-0924; Rotigotine HCl; Neupro
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 50 mg/mL (~142.1 mM)
H2O: ~4.8 mg/mL (~13.5 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.10 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.10 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8415 mL | 14.2074 mL | 28.4147 mL | |
| 5 mM | 0.5683 mL | 2.8415 mL | 5.6829 mL | |
| 10 mM | 0.2841 mL | 1.4207 mL | 2.8415 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00296192 | Completed | Drug: Rotigotine nasal spray Drug: Placebo |
Parkinson's Disease | UCB Pharma | February 2006 | Phase 2 |
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
